EUVIMEDEUVIMED entdecken
Multizentrische Studie

Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study

Estela Giménez, Irene García Cadenas, José Luis Piñana, Eliseo Albert, Lourdes Vázquez, Alejandro Avendaño, Mónica Cabrero, Albert Esquirol, Rodrigo Martino, Javier López-Jiménez, María Ángeles Cuesta, Karem Humala und 10 weitere

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70080 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Estela Giménez und 21 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Service, University Clinical Hospital, INCLIVA Health Research Institute, Valencia, Spain. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, DNA, Viral, Cytomegalovirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: the Carlos III Health Institute, the European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Letermovir (LMV) prophylaxis currently represents the first‐line strategy for preventing clinically significant cytomegalovirus (CMV) infection (CsCMVi) in CMV‐seropositive recipients of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). A wide variety of CMV DNA thresholds for LMV interruption and preemptive antiviral therapy (PET) inception are in place across transplantation centers.

Methods

We evaluated the potential of CMV DNA doubling time (dt) in plasma to distinguish between CsCMVi and abortive CMV infection in allo‐HSCT recipients on primary LMV prophylaxis. Data from the Spanish Hematopoietic Transplantation and Cell Therapy Group multicenter registry included 296 allo‐HSCT patients receiving LMV prophylaxis. Participating centers used a plasma CMV DNA threshold of ≥1000 IU/mL for initiating PET. The CMV DNA dt was calculated from the first two or three positive polymerase chain reaction (PCR) results based on pre‐established criteria.

Results

CMV DNAemia developed in 64 recipients (21.6%) with a total of 88 episodes, of which CsCMVi occurred in 9 recipients (3.04%) and included 10 episodes (one patient had confirmed CMV gastrointestinal disease). A non‐calculable CMV DNA dt had a negative predictive value of 94% for CsCMVi. For initial episodes with calculable CMV DNA dts (4/7 CsCMVi and 8/57 no‐CsCMVi), a threshold of >2.35 days had a specificity of 100% for ruling out CsCMVi.

Conclusion

CMV DNA dt could optimize CMV infection management in allo‐HSCT patients under LMV prophylaxis, independent of the PCR platform used. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsDNA, ViralCytomegalovirusAntiviral AgentsQuinazolinesAcetatesHumansMaleFemaleAdultMiddle AgedTransplantation, HomologousYoung AdultAgedAdolescentSpainViral LoadPolymerase Chain ReactionTransplant Recipients

Stichwörter der Autor:innen

CMV DNA doubling timePCRclinically significant CMV infectioncytomegalovirusletermovir prophylaxispreemptive antiviral therapy“abortive” infection

Substanzen

letermovirDNA, ViralAntiviral AgentsQuinazolinesAcetates

Autor:innen und Institutionen

  • Microbiology Service, University Clinical Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Hematology Service, University Clinical Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Hematology Service, Salamanca University Hospital Complex, Salamanca, Spain.
  • Hematology Service, Ramon y Cajal University Hospital, Madrid, Spain.

Förderung

  • the Carlos III Health Institute
  • the European Regional Development Fund

Zitieren

APA

Giménez, E., Cadenas, I. G., Piñana, J. L., Albert, E., Vázquez, L., Avendaño, A., Cabrero, M., Esquirol, A., Martino, R., López-Jiménez, J., Cuesta, M. Á., Humala, K., Villar, S., Rovira, M., Heras, I., Zudaire, T., Arroyo, I., Zabalza, A., Aguado, B., …, & Spanish Group for Hematopoietic Transplantation (GETH) (2025). Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study. Transplant Infectious Disease. https://doi.org/10.1111/tid.70080

Vancouver

Giménez E, Cadenas IG, Piñana JL, Albert E, Vázquez L, Avendaño A, et al. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study. Transplant Infectious Disease. 2025. doi:10.1111/tid.70080

BibTeX
@article{Gimnez2025,
  author = {Giménez, Estela and Cadenas, Irene García and Piñana, José Luis and Albert, Eliseo and Vázquez, Lourdes and Avendaño, Alejandro and Cabrero, Mónica and Esquirol, Albert and Martino, Rodrigo and López-Jiménez, Javier and Cuesta, María Ángeles and Humala, Karem and Villar, Sara and Rovira, Montserrat and Heras, Inmaculada and Zudaire, Teresa and Arroyo, Ignacio and Zabalza, Amaya and Aguado, Beatriz and Solano, Carlos and Navarro, David and Spanish Group for Hematopoietic Transplantation (GETH), Spanish Group for Hematopoietic Transplantation (GETH)},
  title = {Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70080}
}
Kostenlos starten →